A Al-Maawali1,2, G Yoon1,3, A S Feigenbaum1,4, W C Halliday5, J T R Clarke1, H M Branson6, B L Banwell7, D Chitayat1,8, Susan I Blaser9. 1. Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 2. Department of Genetics, Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman. 3. Division of Neurology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 4. Division of Genetics, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA. 5. Division of Pathology, DPLM, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 6. Division of Paediatric Neuroradiology, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, M5G 1X8, Ontario, Canada. 7. Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 8. The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. 9. Division of Paediatric Neuroradiology, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, M5G 1X8, Ontario, Canada. susan.blaser@sickkids.ca.
Abstract
INTRODUCTION: Infantile neuroaxonal dystrophy (INAD), an autosomal recessive neurodegenerative disorder due to PLA2G6 mutation, is classified both as a PLA2G6-associated neurodegeneration (PLAN) disorder and as one of the neurodegeneration with brain iron accumulation (NBIA) disorders. Age of onset and clinical presentation in INAD is variable. Typically described imaging features of cerebellar atrophy, cerebellar cortex bright FLAIR signal, and globus pallidus iron deposition are variable or late findings. We characterize clinical and neuroimaging phenotypes in nine children with confirmed PLA2G6 mutations and show a useful imaging feature, clava hypertrophy, which may aid in earlier identification of patients. Measurements of the clava confirm actual enlargement, rather than apparent enlargement due to volume loss of the other brain stem structures. METHODS: A retrospective clinical and MRI review was performed. Brain stem measurements were performed and compared with age-matched controls. RESULTS: We identified nine patients, all with novel PLA2G6 gene mutations. MRI, available in eight, showed clava hypertrophy, regardless of age or the absence of other more typically described neuroimaging findings. Brain autopsy in our cohort confirmed prominent spheroid bodies in the clava nuclei. CONCLUSION: Clava hypertrophy is an important early imaging feature which may aid in indentification of children who would benefit from specific testing for PLA2G6 mutations.
INTRODUCTION:Infantile neuroaxonal dystrophy (INAD), an autosomal recessive neurodegenerative disorder due to PLA2G6 mutation, is classified both as a PLA2G6-associated neurodegeneration (PLAN) disorder and as one of the neurodegeneration with brain iron accumulation (NBIA) disorders. Age of onset and clinical presentation in INAD is variable. Typically described imaging features of cerebellar atrophy, cerebellar cortex bright FLAIR signal, and globus pallidus iron deposition are variable or late findings. We characterize clinical and neuroimaging phenotypes in nine children with confirmed PLA2G6 mutations and show a useful imaging feature, clava hypertrophy, which may aid in earlier identification of patients. Measurements of the clava confirm actual enlargement, rather than apparent enlargement due to volume loss of the other brain stem structures. METHODS: A retrospective clinical and MRI review was performed. Brain stem measurements were performed and compared with age-matched controls. RESULTS: We identified nine patients, all with novel PLA2G6 gene mutations. MRI, available in eight, showed clava hypertrophy, regardless of age or the absence of other more typically described neuroimaging findings. Brain autopsy in our cohort confirmed prominent spheroid bodies in the clava nuclei. CONCLUSION:Clava hypertrophy is an important early imaging feature which may aid in indentification of children who would benefit from specific testing for PLA2G6 mutations.
Authors: N Nardocci; G Zorzi; L Farina; S Binelli; W Scaioli; C Ciano; L Verga; L Angelini; M Savoiardo; O Bugiani Journal: Neurology Date: 1999-04-22 Impact factor: 9.910
Authors: A Gregory; S K Westaway; I E Holm; P T Kotzbauer; P Hogarth; S Sonek; J C Coryell; T M Nguyen; N Nardocci; G Zorzi; D Rodriguez; I Desguerre; E Bertini; A Simonati; B Levinson; C Dias; C Barbot; I Carrilho; M Santos; I Malik; J Gitschier; S J Hayflick Journal: Neurology Date: 2008-09-17 Impact factor: 9.910
Authors: Y Wu; Y Jiang; Z Gao; J Wang; Y Yuan; H Xiong; X Chang; X Bao; Y Zhang; J Xiao; X Wu Journal: Eur J Neurol Date: 2008-12-09 Impact factor: 6.089
Authors: Joyce Solomons; Oliver Ridgway; Carol Hardy; Manju A Kurian; Manju Kurian; Sandeep Jayawant; Sarah Hughes; Pieter Pretorius; Andrea H Németh Journal: Dev Med Child Neurol Date: 2013-11-15 Impact factor: 5.449
Authors: M A Illingworth; E Meyer; W K Chong; A Y Manzur; L J Carr; R Younis; C Hardy; F McDonald; A M Childs; B Stewart; D Warren; R Kneen; M D King; S J Hayflick; M A Kurian Journal: Mol Genet Metab Date: 2014-03-29 Impact factor: 4.797
Authors: Mario Mascalchi; Francesco Mari; Beatrice Berti; Emanuele Bartolini; Matteo Lenge; Andrea Bianchi; Laura Antonucci; Filippo M Santorelli; Barbara Garavaglia; Renzo Guerrini Journal: Cerebellum Date: 2017-06 Impact factor: 3.847